Field performance and cost-effectiveness of a point-of-care triage test for HIV virological failure in Southern Africa

Anna, Saura-Lázaro^{1*}, Peter Bock^{2*}, Erika van den Bogaart³, Jessie van Vliet³, Laura Granés⁴, Kerry Nel², Vikesh Naidoo², Michelle Scheepers², Yvonne Saunders², Núria Leal¹, Francesco Ramponi¹, René Paulussen³, Tobias Rinke de Wit⁵, Denise Naniche^{1*}, Elisa López-Varela^{1§*}

1 Barcelona Institute for Global Health (ISGlobal), Hospital Clínic - Universitat de Barcelona, Barcelona, Spain

2 Department of Pediatrics and Child Health, Desmond Tutu TB Centre, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa.

3 Mondial Diagnostics, Amsterdam, The Netherlands.

4 Department of Preventive Medicine and Epidemiology, Hospital Clínic de Barcelona, Spain.

5 Amsterdam Institute for Global Health and Development (AIGHD), Amsterdam, The Netherlands. Amsterdam University Medical Center (UMC) location University of Amsterdam, Department of Global Health, Amsterdam, The Netherlands.

[§] Corresponding author: Elisa López-Varela

C/ Rosselló, 132, 5th 2nd Barcelona, 08036, Spain Phone: (+34) 627136952 Email: <u>elisa.lopez@isglobal.org</u>

*These authors have contributed equally to the work.

E-mail addresses of authors:

- ASL: <u>anna.saura@isglobal.org</u>
- PB: <u>peterb@sun.ac.za</u>
- EB: erika.vandenbogaart@mondialdx.com
- JV: jessie23_09@hotmail.com
- LG: granes@clinic.cat
- KN: klnel@sun.ac.za
- VN: vikeshn@sun.ac.za
- MS: michellebuzzzinter@gmail.com

- YS: <u>ysaunders@sun.ac.za</u>
- NL: nuleal.roca@gmail.com
- FR: francesco.ramponi@isglobal.org
- RP: rene.paulussen@mondialdx.com
- TRW: t.rinkedewit@pharmaccess.org
- DN: denise.naniche@isglobal.org
- ELV: elisa.lopez@isglobal.org

Keywords: CXC chemokine IP-10; point-of-care test; human immunodeficiency virus; therapeutic drug monitoring; cost-effectiveness analysis; Southern Africa.

1 Abstract

Introduction: Antiretroviral therapy (ART) monitoring using viral load (VL) testing is 2 challenging in high-burden, limited-resources settings. Chemokine IP-10 (interferon gamma-3 induced protein 10) strongly correlates with human immunodeficiency virus (HIV) VL. Its 4 determination could serve to predict virological failure (VF) and to triage patients requiring VL 5 testing. We assessed the field performance of a semi-quantitative IP-10 lateral flow assay (LFA) 6 for VF screening in South Africa, and the cost-effectiveness of its implementation in Mozambique. 7 8 Methods: A cross-sectional study was conducted between June and December 2021 in three primary health clinics in the Western Cape. Finger prick capillary blood was collected from adults 9 on ART for ≥ 1 year for direct application onto the IP-10 LFA (index test) and compared with a 10 plasma VL result ≤ 1 month prior (reference test). We estimated the area under the receiver 11 operating characteristic curves (AUC), sensitivity and specificity, to evaluate IP-10 LFA 12 prediction of VF (VL>1,000 copies/mL). A decision tree model was used to investigate the cost-13 effectiveness of integrating IP-10 LFA combined with VL testing into the current Mozambican 14 ART monitoring strategy. Averted disability-adjusted life years (DALYs) and HIV infections, and 15 incremental cost-effectiveness ratios were estimated. 16

Results: Among 209 participants (median age 38 years and 84% female), 18% had VF. Median 17 IP-10 LFA values were higher among individuals with VF compared to those without (24.0 vs. 18 14.6; p<0.001). The IP-10 LFA predicted VF with an AUC=0.76 (95% confidence interval (CI) 19 20 0.67–0.85), 91.9% sensitivity (95%CI 78.1%–98.3%) and 35.1% specificity (95%CI 28.0%– 42.7%). Integrating the IP-10 LFA in a setting with 20% VF prevalence and 61% VL testing 21 coverage could save 13.0% of costs and avert 14.9% of DALYs and 55.7% new HIV infections. 22 23 Furthermore, its introduction was estimated to reduce the total number of routine VL tests required for ART monitoring by up to 68%. 24

Conclusions: The IP-10 LFA is an effective VF triage test for routine ART monitoring.
 Combining a highly sensitive, low-cost IP-10 LFA-based screening with targeted VL confirmatory
 testing could result in significant healthcare quality improvements and cost savings in settings with
 limited access to VL testing.

30 Introduction

For people living with human immunodeficiency virus (PLHIV) on antiretroviral therapy (ART), 31 viral load (VL) testing is the gold standard approach to timely monitor treatment effectiveness, 32 identify virological failure (VF) and establish the need to switch to a second-line ART regimen 33 34 [1]. Prior to the roll-out of dolutegravir in 2019, reported VF rates in Sub-Saharan Africa (SSA) 35 varied from 5% to 25% [2,3]. VF has severe clinical consequences due to the resulting immunosuppression; in addition 80-90% of subjects with detectable viremia may eventually 36 37 harbor viruses resistant to first-line ART [2–4]. In the absence of adequate ART monitoring tools, PLHIV who have VF can remain on failing regimens with clinical deterioration, onward HIV 38 transmission and gradual loss of ART effectiveness on individual and population levels. 39

40

The recent and rapid scale-up of ART coverage, with 28.7 million PLHIV receiving ART in 2021 41 [5], has increased the demand for VL tests. Access to VL testing is limited in many low- and 42 middle-income countries (LMIC) with high HIV burden, particularly in SSA, due to costs and lack 43 of qualified human resources and infrastructure [6,7]. Data from 2018 showed that in 6 SSA 44 45 countries assessed the mean proportion of PLHIV on ART receiving at least one VL test was below 75%, and <55% in two of them [8]. Enabling routine access to VL testing to promptly detect VF 46 is critical to reduce HIV burden, morbidity and mortality. In LMIC where widespread use of 47 nucleic acid-based VL tests is not a realistic option, reliance on dried blood spots (DBS), point-of-48 49 care (POC) technologies, or other alternative specimen types or technologies is necessary to 50 expand access to VL testing.

51

52 IP-10 (interferon gamma-induced protein 10) is a human chemokine that strongly correlates with 53 HIV VL [9]. Its assessment in plasma can serve as a highly sensitive screening tool to identify PLHIV on ART at risk of VF [10,11]. Mondial Diagnostics in The Netherlands developed an IP-54 55 10 rapid test for finger prick capillary blood samples and plasma, in collaboration with the 56 Barcelona Institute for Global Health (ISGlobal) and the Amsterdam Institute for Global Health and Development (AIGHD). This semi-quantitative lateral flow assay (LFA) consists of a dried 57 detection reagent deposited in a test tube and a dipstick with a test line to measure IP-10 and a 58 control line to confirm assay validity. We aimed to evaluate the field performance of this first IP-59 10 LFA prototype as a VF screening test in PLHIV on ART in Cape Town, South Africa. We also 60

assessed the cost-effectiveness of implementing the IP-10 LFA in three different ART monitoring

algorithms in a setting with limited access to routine VL testing using Mozambique as an example

63

64 Methods

65

66 Study design, setting and population

A cross-sectional study was conducted between June and December 2021 in three primary health 67 clinics, Kraaifontein Community Health Centre, Ivan Toms Centre for health and Bloekombos 68 Clinic, in the Cape Metro, Western Cape, South Africa. The Cape Metro district has approximately 69 48,400 PLHIV on ART, a relatively high VL coverage of 72-89% [12,13], and an overall VL 70 suppression rate, defined as undetectable VL, of 84% among individuals with VL result [14]. HIV 71 treatment and care are offered free of charge and VL testing for ART monitoring is recommended 72 to be performed annually [15]. We strategically selected these clinics due to their relatively high 73 74 programmatic VL coverage, which facilitated the effective evaluation of the IP-10 LFA's field performance by utilizing existing VL data and infrastructure. 75

76

77 PLHIV aged ≥ 18 years on ART for at least 12 months without treatment interruptions in the previous 3 months attending the clinic were pre-screened for study participation pursuing an 78 79 enriched enrolment of PLHIV experiencing VF to ensure 85% statistical power. Assuming a VF prevalence of 25% and a sensitivity of the IP-10 LFA above 90%, we calculated that a sample size 80 of 35 PLHIV experiencing VF would provide a significant level of 0.05 and a confidence interval 81 (CI) with a half-width of 0.1. Individuals presenting with symptoms suggestive of COVID-19, 82 such as cough, shortness of breath, sore throat, anosmia, ageusia, conjunctivitis, and weight loss 83 >1.5kg, were excluded [16]. 84

85

86 Study visit procedures

After obtaining informed consent, a research assistant collected participants' socio-demographic
and clinical information by using an electronic survey. Each participant underwent phlebotomy

and finger prick capillary blood testing with the IP-10 LFA (index test) performed by a trainednurse.

91

The IP-10 LFA was performed in a controlled temperature environment as follows: i) 50 μ L of 92 assay fluid were dispensed into the test tube, followed by 2 µL of freshly collected capillary blood 93 using a precision pipette; ii) the dipstick was immersed into the reaction mixture for 20 minutes; 94 iii) after time elapsed, the dipstick was removed from the test tube and added to the clean, portable, 95 96 battery-operated LFA reader (Cube Reader, Chembio Diagnostics, Germany), which provided a numeric readout in arbitrary units (scale: 0-10,000, 0.1 increments) proportional to the IP-10 97 concentration in the test sample. The IP-10 LFA result was not shared with the participant. 98 99 100 If the participant had a routine VL completed in the 30 days prior to visit, this result was accessed and captured in the study database. If no routine VL result was available, the study team completed 101 a VL test through using an aliquot of the venous blood collected. 102

103

Anti-coagulated venous blood samples were transported to the Clinical Laboratory Services in
 Cape Town where plasma was separated and cryopreserved within 4 hours of sample collection,
 prior to being shipped to Mondial Diagnostics for further test validation.

107

108 Laboratory procedures

Plasma HIV RNA levels (VL result) were determined according to routine practice using the 109 110 Abbott Real-Time HIV1/2 Polymerase Chain Reaction (PCR) (reference test). Quantitative measurement of IP-10 concentrations in plasma samples was conducted at Mondial Diagnostics 111 112 using the Human CXCL10/IP-10 Quantikine ELISA kit (R&D Systems, USA), according to 113 manufacturer's specifications. Plasma specimens were also blindly assayed with the IP-10 LFA using 1 μ L of plasma sample from the same test batch as the one used for capillary blood at study 114 115 sites. The outcome was determined by Cube Reader as well as visually by two independent readers (scale: 0-4, 0.5 increments). When the Cube Reader results differed \geq 2-fold between plasma and 116 capillary blood, the IP-10 LFA was repeated, and the average result of both tests was included in 117 the analysis. The IP-10 LFA was validated using both capillary blood and plasma against HIV 118 RNA levels and ELISA IP-10 measurements. 119

120 Statistical analysis

Proportions for categorical variables and the median and interquartile range (IOR) for continuous 121 122 variables were calculated and compared using X2 and nonparametric Mann-Whitney U test, respectively. Spearman test was used to assess correlation coefficients for continuous variables. 123 Logistic regression analysis with penalized likelihood was performed to assess the capacity of the 124 IP-10 LFA and the socio-demographic and clinical variables to predict VF [17], defined as 125 VL>1,000 copies/mL. A multivariable logistic regression model was built by including all 126 variables with a p-value <0.20 in the bivariable analyses (IP-10 LFA values were fixed), followed 127 by backward stepwise selection, where variables with p-values <0.05 could enter the model 128 whereas a p-value <0.10 was required to be retained. A 5-fold cross-validation was used to estimate 129 average accuracy. Receiver operating characteristic analyses were conducted to obtain the area 130 under the curve (AUC), as well as sensitivity, specificity and predictive values for different IP-10 131 LFA cut-off values. Optimal cut-off values to screen for VF were selected prioritizing a sensitivity 132 above 90%, as the IP-10 LFA was validated as a triage test. Stata version 16 was used for the 133 analyses. 134

135

136 Cost-effectiveness analysis

We developed a decision tree model (Figure 1) to compare the current standard of care of using 137 138 VL testing only for ART monitoring (Strategy 1, Supplementary Figure 1) with 3 alternative strategies integrating the IP-10 LFA combined with a confirmatory VL test (Supplementary Figure 139 2): i) IP-10 LFA + VL test performed immediately after an IP-10 positive result (Strategy 2a), ii) 140 IP-10 LFA + VL test performed 3 months after an IP-10 positive result and after receiving 141 enhanced adherence counselling (EAC) (Strategy 2b), and iii) IP-10 LFA + a second IP-10 LFA 142 3 months after an IP-10 positive result and EAC + VL test performed only among clients who test 143 positive for the second IP-10 LFA (Strategy 2c). Considering that the IP-10 LFA was developed 144 to be implemented in settings where access to VL testing is limited, we assessed its cost-145 effectiveness in Mozambique, where the global VL testing coverage was 61% with a VF 146 147 prevalence of 20% in 2021 [18].









Figure 1. 1a) A decision tree model for antiretroviral therapy (ART) monitoring comparing 149 the standard of care of using viral load (VL) testing only in a two-step algorithm 150 151 recommended by the World Health Organization with three proposed algorithms where the 152 **IP-10** lateral flow assay (LFA) is integrated combined with VL confirmatory testing: 1b) immediately after performing the IP-10 LFA; 1c) 3 months later after receiving enhanced 153 154 adherence counselling (EAC); 1d) 3 months later after receiving EAC and after a second positive IP-10 LFA result. Each branch depicts individual steps of ART monitoring algorithm 155 and is conditional on the previous step. The grey square node represents a decision node, grey 156 circular nodes represent chance nodes, and grey triangles illustrate terminal nodes. PLHIV: people 157 living with HIV, VF: virological failure. 158

159

The analysis was conducted from the healthcare system perspective. We adopted a life-time 160 horizon and simulated a cohort of 1,000 adults living with HIV who initiated ART at 25 years of 161 age. Effects on health were measured using disability-adjusted life years (DALYs) averted, and 162 new HIV infections averted (HIA). DALYs were derived from the disability weights according to 163 164 the Global Burden of Disease Study 2019 [19]. We made the assumption that transmission only occurred from our cohort of 1,000 individuals to a number (n) of other individuals, with n taking 165 values of 1 or 4 (low and high transmission scenarios, respectively). We assumed that all PLHIV 166 with undiagnosed VF, and therefore untreated, generated new HIV cases. Costs included treatment 167 (both first and second-line ART regimens) and monitoring, and we used unit costs of US\$3 for IP-168 10 LFA and of US\$51 for VL test (including reagents, transport and staff) [20]. Costs were 169 170 expressed in 2022 US\$ and we applied a 3% discount rate [21,22]. All data used are detailed in 171 Supplementary Table 1. Results were expressed as incremental cost-effectiveness ratios (ICER), calculated as the additional costs to avert one disability-adjusted life year (DALY) or a new HIV 172 173 infection. A one-way sensitivity analysis was undertaken to investigate the effect of uncertainty in model parameters. Microsoft Excel 2019 was used for the analyses. 174

175

176 **Ethical considerations**

The study protocol was approved by the University Health Research Ethics Committee in Cape
Town (Approval Nr. N20/02/25) and the Clinical Research Ethical Committee of the Hospital

179 Clinic in Barcelona (Approval Nr. HCB/2021/0656). All study participants completed informed180 consent.

181

182 **Results**

183

184 Participant characteristics

We enrolled 209 participants with a median age of 38 years (IQR, 31-44), of whom 83.7% (n=175) were women (Table 1). Median time since HIV diagnosis was 7 years (IQR, 4-10) and median time on ART was 6.5 years (IQR, 4.2-9.4). The most common treatment regimen was Tenofovir/Lamivudine/Dolutegravir (83.3%), and 87.1% reported not missing any ART dose during the last month.

190

191 Table 1. Socio-demographic and clinical characteristics associated with virological failure

192 (VF) (viral load >1,000 copies/mL) among study participants (n=209). Adjusted odds ratios

193 from logistic regression analyses.

	N (%) or median (IQR)							95%CI	p-value
	Total		VL <u>:</u> copi	VL≤1000 V copies/mL co		VL>1000 copies/mL			
	(n	=209) ^a	(n=171)		(n	(n=37)			
Biological sex									
Male	34	(16.35)	28	(16.28)	6	(16.22)			
Female	175	(83.73)	144	(83.72)	31	(83.78)			
Age (years)	38	(31-44)	37	(31-44)	39	(34-46)			
Employment									
Employed	43	(20.57)	38	(22.09)	5	(13.51)			
Part-time	21	(10.10)	14	(8.14)	7	(18.92)			
Not employed	145	(69.38)	120	(69.77)	25	(67.57)			
Marital status									
Married ^b	58	(27.75)	51	(29.65)	7	(18.92)			
Single	139	(66.51)	112	(65.12)	27	(72.97)			
Divorced	7	(3.35)	7	(4.07)	0	(0.00)			

Widowed	5	(2.39)	2	(1.16)	3	(8.11)	
Educational level							
No primary	10	(1 78)	6	(2, 40)	4	(10.81)	
school	10	(4.78)	0	(3.49)	4	(10.01)	
Primary	135	(64 59)	112	(65.12)	23	(62,16)	
school	155	(04.39)	112	(05.12)	23	(02.10)	
Secondary	58	(27.75)	40	(28.49)	0	(24.32)	
school	50	(21.15)	47	(20.47))	(24.32)	
Post-	2	(0.96)	1	(0.58)	1	(2,70)	
secondary school	2	(0.90)	1	(0.50)	1	(2.70)	
University	4	(1.91)	4	(2.33)	0	(0.00)	
BMI ^c (n=202)							
Normal	58	(28.71)	46	(27.88)	12	(32.43)	
weight	50	(20.71)	40	(27.00)	12	(32.43)	
Underweight	2	(0.99)	1	(0.61)	1	(2.70)	
Overweight	63	(31.19)	50	(30.30)	13	(35.14)	
Obesity	79	(39.11)	68	(41.21)	11	(29.73)	
Previous							
confirmed	7	(3 35)	5	(2.91)	2	(5.41)	
COVID-19	,	(5.55)	5	(2.91)	2	(3.41)	
diagnosis							
Previous COVID-	1	(0.48)	1	(0.58)	0	(0, 00)	
19 hospitalization	1	(0.40)	1	(0.50)	Ū	(0.00)	
Pregnancy							
(n=175)							
No or	170	(97.14)	141	(97.92)	29	(93 55)	
unknown ^d	170	()7.14)	141	()1.)2)	2)	()3.33)	
Yes	5	(2.86)	3	(2.08)	2	(6.45)	
Hypertension	22	(10.53)	17	(9.88)	5	(13.51)	
Diabetes	3	(1.44)	2	(1.16)	1	(2.70)	
Hepatitis B (n=65)	3	(4.62)	1	(2.44)	2	(8.33)	
Epilepsy	3	(1.44)	2	(1.16)	1	(2.70)	
Symptoms at the	4	(1.91)	3	(174)	1	(2,70)	
study visit ^e		(1)1)	U	(11) 1)		(21/0)	
Current TB	1	(0.48)	0	(0.00)	1	(2.70)	
Previous or							
current TB	51	(24.40)	39	(22.67)	12	(32.43)	
treatment							
WHO stage at							
ART initiation							
Stage 1 or 2	164	(78.47)	136	(79.07)	28	(75.68)	

Stage 3 or 4	45	(21.53)	36	(20.93)	9	(24.32)			
WHO stage at the									
study visit									
Stage 1 or 2	159	(76.08)	132	(76.74)	27	(72.97)			
Stage 3 or 4	50	(23.92)	40	(23.26)	10	(27.03)			
IP-10 LFA	16.2	(11.9-	146	(11.3-	24	(17.6-	2.27.8	1.59-	-0.001
reading f (n=208)	10.2	22.8)	14.0	20.0)	24	36.3)	2.278	3.22	<0.001
Days since last	7	$(A_{-}1A)$	8	(5-14)	6	(2 - 12)			
VL	/	(4-14)	0	(3-14)	0	(2-12)			
Years since ART	65	(1201)	6 33	(4.2-	7.50	(4.8-			
initiation	0.5	(4.2-9.4)	0.55	9.0)	7.50	11.1)			
Years since HIV	7	(4.10)	6	(4.0)	0	(5.12)	1 1 1	0.995-	0.061
diagnosis	/	(4-10)	0	(4-9)	0	(3-12)	1.11	1.23	0.001
Missed ART ^h									
None	182	(87.08)	158	(91.86)	24	(64.86)	Ref.		
At least once	27	(12.02)	14	(9, 14)	12	(25.14)	5 27	2.07-	-0.001
dose a month	21	(12.92)	14	(8.14)	15	(33.14)	5.57	13.05	<0.001
Current ART									
regimen									
TDF+3TC+DTG	174	(83.25)	150	(87.21)	24	(64.86)			
TDF+FTC+EFV	21	(10.05)	14	(8.14)	7	(18.92)			
Others	14	(6.70)	8	(4.65)	6	(16.22)			

195 Legend of table:

^aFor those variables with missing values, the total number of observations included is indicated next to the name of the variable.

^bThis category includes married, civil union or legal partnership.

^d All of them were unknown, except one.

200 ^e After COVID-19 screening, symptoms assessed were fever, night sweats, myalgia, fatigue, headache, diarrhoea and skin rash.

201 ^fIP-10 LFA values were log-transformed for a better adjustment of skewed data.

202 ^g For OR calculation, IP-10 reading values were categorized by increments of 10-units. Therefore, an increase of 10 units in the

203 IP-10 reading value corresponds to a 2.38 OR of having VF.

^hSelf-reported ART adherence.

205 Abbreviations: 3TC: lamivudine, ART: antiretroviral therapy, aOR: adjusted odds ratio, BMI: body mass index, CI: confidence

206 interval, DTG: dolutegravir, FTC: emtricitabine, EFV: efavirenz, IQR: interquartile range, LFA: lateral flow assay, Ref: reference

207 category, TB: tuberculosis, TDF: tenofovir, VL: viral load.

- 209 Median time since last VL determination was 7 days (IQR, 4-14). A total of 17.7% (95% CI, 12.5-
- 210 22.9) had VF and among those, median VL was 10,615 copies/mL (IQR, 3,698-49,311). We
- excluded one participant from the evaluation of the IP-10 LFA performance analysis due to an

- 212 invalid reading value.
- 213

214 Field performance

- 215 Median IP-10 LFA reading values, hereinafter referred to as `IP-10 LFA values', were
- significantly higher among individuals with VF (24.0 vs 14.6; p<0.001). Among individuals
- 217 (n=57) with detectable VL (>50 copies/mL), IP-10 LFA values showed a significant moderate
- 218 correlation with VL (ρ =0.46, p<0.001).
- 219 Multivariable analysis revealed that IP-10 LFA values, self-reported ART adherence and time
- since HIV diagnosis were associated with VF (Table 1). The univariable analysis (Supplementary
- Table 2) showed that IP-10 LFA values were associated with VF (odds ratio (OR), 2.38 per 10
- 222 units-increase; 95%CI, 1.66-3.40). The estimated AUC was 0.76 (95%CI, 0.67-0.85) and the
- averaged 5-fold cross validated AUC was 0.77 (95%CI, 0.64-0.84).
- 224 Since no differences were found between the AUC of univariable and multivariable models, the
- former was selected for assessing the accuracy of IP-10 LFA in predicting VF at various cut-off
- values (Figure 2a). Using an IP-10 LFA value of \geq 12.8, the model identified VF with 91.9%
- sensitivity (95%CI, 78.1%-98.3%) and 35.1% specificity (95%CI, 28.0%-42.7%) (Figure 2b)
- resulting in a positive predictive value (PPV) of 23.4% (95%CI, 16.8%-31.2%) and a negative
- predictive value (NPV) of 95.2% (95%CI, 86.7%-99.0%) in the current study population (17.7%
- 230 VF prevalence) (Supplementary Figure 3).



b	Cut-off value	Sensitivity (%)	Specificity (%)
	7.3	100.0	3.5
	10.9	97.3	20.5
	12.0	94.6	29.2
	12.8	91.9	35.1
	13.6	88.2	40.9
	14.6	86.5	49.1
	14.9	83.8	51.5
	16.1	81.1	55.0
	1		

231

Figure 2. Performance of the IP-10 lateral flow assay (LFA) reading values (arbitrary units,
Cube Reader) models in predicting virological failure (VF). (a) Comparison between the area
under the curve (AUC) for univariable and multivariable models. (b) Univariable model cut-off
IP-10 LFA reading values with their respective sensitivity and specificity values.

237 Laboratory validations

Validation of the IP-10 LFA either on capillary blood or plasma against IP-10 ELISA demonstrated a good level of correlation between the two assays, which was higher when the IP-10 LFA was performed on plasma (ρ =0.89, p<0.001) compared to finger prick capillary blood (ρ =0.74, p<0.001) (Supplementary Figure 4). Overall, IP-10 LFA values measured in plasma were lower than in capillary blood but remained significantly higher among individuals with VF (median values of 16.6 vs. 11.9; p<0.001).

The AUC of the IP-10 LFA in plasma to detect VF was similar to capillary blood, regardless of whether the test was read by Cube Reader (0.77; 95%CI, 0.67-0.86) or visually (0.78; 95%CI, 0.69-0.87). When using a cut-off value of 10.7 for the Cube Reader and of 1.5 for visual results, the IP-10 LFA on plasma predicted VF with the same sensitivity as in blood, but the specificity increased to 43.6% (95%CI, 36.1%-51.4%) and 48.8% (95%CI, 41.2%-56.6%), respectively (Table 2).

250

251 Table 2. Diagnostic accuracy of the IP-10 LFA compared to Real Time- Polymerase Chain

- Reaction (PCR) for the detection of virological failure (VF), defined as viral load >1,000
- 253 copies/mL.

	Se	Sp	PPV	NPV	Kappa values
	(95% CI)				
IP-10 LFA (capillary	91.9	35.1	23.4	95.2	0.126
blood, Cube Reader)	(78.1 – 98.3)	(28.0 – 42.7)	(16.8 – 31.2)	(86.7 – 99.0)	(-0.081 – 0.333)
IP-10 LFA (plasma,	91.9	43.6	26.0	96.2	0.178
Cube Reader)	(78.1 – 98.3)	(36.1 – 51.4)	(18.7 – 34.3)	(89.2 - 99.2)	(-0.011 – 0.366)
IP-10 LFA (plasma,	91.9	48.8	27.9	96.6	0.214
visual score)	(78.1 – 98.3)	(41.2 – 56.6)	(20.1 – 36.7)	(90.3 - 99.3)	(0.037 – 0.392)

254 Legend of table:

255 IP-10 LFA values were log-transformed for a better adjustment of skewed data.

^{256 &}lt;u>Abbreviations:</u> CI: confidence interval, LFA: lateral flow assay, NPV: negative predictive value, PPV: positive predictive value,

²⁵⁷ Se: Sensitivity, Sp: Specificity, VF: virological failure, VL: viral load.

259 Cost-effectiveness analysis

260 Costs and health outcomes associated with various ART monitoring strategies are reported in 261 Table 3, ranked by costs in ascending order. In a low transmission scenario (1:1), Strategy 2b was 262 the least expensive strategy with the greatest number of DALYs averted. Compared to the current standard of care (Strategy 1), Strategy 2b could reduce 1.1% of life-time costs and 10.1% of the 263 DALYs associated with HIV. In a high transmission scenario (1:4), Strategy 2b was still the least 264 expensive, associated not only with 13.0% lower costs compared to current standard of care, but 265 also with 14.9% DALYs and 55.7% new HIV infections fewer. Compared to Strategy 2b, Strategy 266 2c was more expensive, but offered better health outcomes, so it was associated to an ICER of 267 US\$1,995and US\$2,827 per DALY and HIA averted, respectively. Strategies 2b and 2c were 268 estimated to reduce up to 46.9% and 67.9% respectively, of the total routine VL tests necessary 269 270 for ART monitoring.

271 Table 3. Health (DALYs and new HIV infections averted) and economic outcomes of antiretroviral therapy (ART) monitoring

strategies. Strategies are listed and compared in order of lowest to highest cost, by low and high HIV transmission scenarios (1:1

- and 1:4, respectively).
- 274

Strategy	Total costs (2022 US\$)	Difference in costs, US\$	Total DALYs	DALYs averted	ICER (US\$/DALY averted)	Total new HIV infections	New HIV infections averted	ICER (US\$/HIV infection averted)
Low transmission scenario (1:1)								
IP-10 LFA + VL test 3 months later								
after an IP-10 positive result and EAC (Strategy 2b)	3,897,852	-	5,886.1	-	-	40.7	-	-
IP-10 LFA + VL test immediately after an IP-10 positive result (Strategy 2a)	3,912,788	14,936	5,998.9	-112.8	Dominated by Strategy 2b	43.4	-2.7	Dominated by Strategy 2b
Using VL testing only (Strategy 1)	3,940,416	42,546	6,550.7	-664.6	Dominated by Strategy 2b	91.8	-51.1	Dominated by Strategy 2b
IP-10 LFA + VL test 3 months later after an IP-10 positive result and EAC, and after a second positive IP-10 LFA (Strategy 2c)	4,032,908	135,056	5,901.9	-15.9	Dominated by Strategy 2b	34.9	5.8*	24,607*
High transmission scenario (1:4)								
IP-10 LFA + VL test 3 months later after an IP-10 positive result and EAC (Strategy 2b)	4,384,756	-	6,227.9	-	-	162.8	-	-

IP-10 LFA + VL test immediately after an IP-10 positive result (Strategy 2a)	4,431,989	47,233	6,363.4	-135.5	Dominated by Strategy 2b	173.6	-10.8	Dominated by Strategy 2b
IP-10 LFA + VL test 3 months later after an IP-10 positive result and EAC, and after a second positive IP-10 LFA (Strategy 2c)	4,450,373	65,517 [†]	6,195.0	32.9 [†]	1,995†	139.5	23.2 [†]	2,827†
Using VL testing only (Strategy 1)	5,038,771	654,015	7,321.8	-1,093.9	Dominated by Strategy 2b	367.1	-204.4	Dominated by Strategy 2b

275 Legend of table:

276 A dominated scenario occurs when the comparator is less costly but more effective. <u>Abbreviations:</u> DALY: disability-adjusted live years, EAC: enhanced adherence counselling,

277 ICER: incremental cost-effectiveness ratio, LFA: lateral flow assay, VL: viral load. †Estimated by comparing Strategy 2c against Strategy 2b, after eliminating dominated strategies.

When comparing Strategy 2c against 2b, the one-way sensitivity analysis (Figure 3) showed that 278 in a high transmission scenario when using the minimum value estimated for VF (10%) in 279 280 Mozambique in 2021 [13], Strategy 2c was even more expensive but more effective than 2b with an ICER over US\$7,500/DALY averted. However, when using the maximum value estimated for 281 VF prevalence of 31% [13], Strategy 2c dominated Strategy 2b as it had lower costs and improved 282 outcomes. Strategy 2c also dominated when decreasing VL coverage to 48% or VL specificity to 283 96.1%, and when increasing IP-10 LFA sensitivity to 98.3%. Lastly, we found that as the VL 284 suppression rate after EAC decreased, the ICER comparing Strategy 2c against 2b also decreased. 285 Results are detailed in Supplementary Table 3. 286





288



parameters. The black vertical solid line represents the baseline value of the ICER (1,995
US\$/DALY averted). The area shaded dotted grey represents a dominant scenario by Strategy 2c
(lower costs and improved outcomes). Parameters that have the highest impact on the model are
shown at the top, while the least impact is displayed at the bottom. *Strategy 2b dominated Strategy
2c (lower costs and improved outcomes), so the ICER was not estimated. DALY: disabilityadjusted live years, EAC: enhanced adherence counselling, LFA: lateral flow assay, VL: viral load.

301

302 **Discussion**

This study demonstrated that the IP-10 LFA performed as a highly sensitive VF screening test and 303 304 a cost-saving tool for ART monitoring in settings with limited access to VL testing. Integrating 305 the IP-10 LFA combined with a confirmatory VL test would allow to rule out VF in PLHIV who 306 are stable and test negative for IP-10 LFA, thus allowing to prioritize available VL capacity for 307 those for whom treatment failure is suspected. Compared to the standard of care, the implementation of IP-10 LFA would expand access to better health outcomes for lower costs. The 308 choice of using IP-10 LFA once (Strategy 2b) or twice (Strategy 2c) in the WHO-aligned algorithm 309 310 is context-specific and would depend on local factors as well as the cost-effectiveness threshold.

311

Even though most of PLHIV with VF were identified by IP-10 testing, up to 8% yielded a false negative result. Especially in LMIC the consequences of such VF misdiagnosis need to be weighed against the morbidity and mortality risks associated with a higher proportion of PLHIV not having access to ART monitoring at all. Self-reported treatment adherence was a strong predictor of VF in this study; further investigation should explore if its assessment integrated in the algorithm can help identify IP-10 false negative results.

318

Regarding specificity, IP-10 is not specific to HIV and increases in other infections such as tuberculosis or COVID-19 [23,24]. With a moderate specificity, such as that observed in this study, approximately 43% of participants without VF would be correctly identified as such with the IP-10 test when using plasma, while the remaining 57% without VF would have a positive IP-10 LFA. HIV VL is also sensitive to conditions which activate the immune system such as co-infections and vaccines [25,26]. Nevertheless, based on the proposed implementation algorithms, individuals

with a positive IP-10 result would receive EAC followed by a 3-month confirmatory VL testing,
a non-invasive intervention of which the only consequence could be to reinforce their adherence
to treatment.

328

This IP-10 LFA prototype performed as well as an ELISA test with a sensitivity >90% and a moderate specificity, which improved when using plasma (43%) instead of capillary blood (35%). This is likely due to the interindividual variation in hematocrit levels that affects the actual plasma volume being tested from a drop of capillary blood. Nevertheless, moderate specificity is a common feature of screening tests which typically require confirmation with a more specific diagnostic test [27].

335

Based on the economic evaluation, we estimated that the ART monitoring algorithm integrating the IP-10 LFA is superior to the standard of care DBS-based VL testing only in terms of costs and health outcomes. Despite the necessity of confirming positive IP-10 LFA results with VL testing, the introduction of the IP-10 LFA as a VF screening test could reduce more than a half the number of VL tests for routine ART monitoring.

341

342 The IP-10 LFA integrated in Strategy 2b was estimated to yield the lowest costs and to avert the 343 greatest number of DALYs in a setting with low HIV transmission. In a high HIV transmission 344 setting, Strategy 2c was demonstrated to be more effective than Strategy 2b, but at the expense of 345 additional costs, US\$1,995 for each additional DALY averted and US\$2,827 for each additional 346 new HIA. Both ICERs were above the recommended cost-effectiveness threshold (CET) of 347 US\$250 to US\$750 (0.5 to 1.5 times the gross domestic product per capita of Mozambique in 2021 348 [28,29], and alternative CET estimates based on opportunity costs [30,31]). Strategy 2c was hence 349 not cost-effective when compared to Strategy 2b, although it was still less expensive with better health outcomes than standard of care. However, Strategy 2c demonstrated superiority to 2b 350 351 (cheaper and more effective) when it was modelled in a scenario with a higher VF prevalence 352 (parameter with the largest impact on the ICER), higher sensitivity of the IP-10 LFA (screening 353 test) and lower specificity and coverage of the VL test (confirmatory test), the key determinants of the utility of a screening program prompting the use of a second screening with the IP-10 LFA 354 [32]. Additionally, Strategy 2c appeared to be potentially cost-effective with an ICER of US\$755 355

when the rate of VL suppression after receiving EAC was lower. This suggests that the use of the
IP-10 LFA twice may be cost-effective in settings with a high prevalence of HIV drug resistance.

359 The major limitation of this study is the small sample size of PLHIV experiencing VF, resulting in relatively wide confidence intervals, especially for the sensitivity and NPV. Another potential 360 361 limitation may be the interference of unidentified COVID-19 infections, participants with asymptomatic infections may have entered the study, and other undiagnosed co-infections. Future 362 studies should explore the role of co-infections recruiting a higher number of PLHIV with VF to 363 decrease the uncertainty of the estimates. Regarding the cost-effectiveness analysis, the model was 364 static so the number of HIA may be underestimated [33]. Lastly, we found major pricing 365 discrepancies of VL testing across the literature [34–37], but the cost of VL testing had only a 366 367 minor effect on the ICER.

368

The IP-10 LFA is a low-cost and easy-to-read rapid test which can be performed by minimally 369 370 trained personnel. It also offers the advantage of providing results to patients on the same day the 371 test is performed, which can potentially have a positive influence on their behavior and adherence. Therefore, the IP-10 LFA represents a true POC screening test for VF [38] compared with the 372 373 several POC VL testing technologies developed in recent years, including the WHO-prequalified Cepheid GeneXpert[®] and Abbott m-PIMA[™], which are device-based semi-POC tests with 374 375 limited portability and increased costs (US\$25-US\$30, reagents only) [37,39-41]. Moreover, the test read visually performed as well as when using a Cube Reader, with the potential of simplifying 376 377 its use without the need of an extra device.

378

379 The advent of POC technologies coincides with the rollout of the differentiated HIV care models 380 in many LMIC, new less resource-demanding and more client-centered services which typically focused on providing ART to stable PLHIV. The implementation of the IP-10 LFA would expand 381 and improve the access to differentiated HIV care by a quicker triage of PLHIV on ART into 382 383 differentiated care pathway, same-day results, fewer clinical visits and faster clinical making-384 decision [42]. The IP-10 LFA may also be amenable to community-based and self-testing, which helps improve access to ART monitoring particularly in hard-to-reach populations, such as people 385 who inject drugs, migrants and PLHIV living in remote or conflict settings [43,44]. 386

387 Conclusions

Combining a highly sensitive, low-cost IP-10 LFA-based VF screening with VL confirmatory testing in an optimized algorithm could provide a greatly needed ART monitoring tool with the potential to fill the gap in VL testing access in LMIC. Successful integration of the IP-10 LFA into HIV services must consider PLHIV needs, co-infections, clinic flows, staff training, quality control and supply chain management at decentralized sites. Thus, future studies to evaluate sustainability, acceptability and feasibility of this new IP-10 LFA, as well as to explore its utility in other potential high-risk groups, like children, adolescents, and pregnant women are highly recommended.

395

396 Competing interests

E.B and J.V. are employed by Mondial Diagnostics (Amsterdam, The Netherlands). R.P. is
managing director of Mondial Diagnostics (Amsterdam, The Netherlands). All other authors have
no conflict of interests to declare.

400

401 Authors' contributions

P.B., T.R.W., D.N. and E.L.V. were responsible for conceptualization and study design. K.N., 402 403 V.N., M.S. and Y.S. recruited subjects and collected and validated clinical data. K.N., V.N., M.S. 404 and Y.S. coordinated sample collection and processing at the field. E.B. and J.V. performed 405 biomarker quantification at the laboratory and validation of the data. A.S.L., E.B. and L.G. performed the statistical analysis. A.S.L., N.L. and F.R. performed the cost-effectiveness analysis. 406 A.S.L., P.B., E.B., L.G., N.L., F.R., D.N. and E.L.V. interpreted the data. A.S.L. drafted the paper. 407 408 P.B., E.B., M.S., R.P., T.B.W., D.N. and E.L.V, performed the critical data review and revision of 409 manuscript writing. All authors read and approved the final version of the manuscript.

410

411 Acknowledgements

We acknowledge support from the Spanish Ministry of Science and Innovation and State Research
Agency through the "Centro de Excelencia Severo Ochoa 2019-2023" Program (CEX2018000806-S), and support from the Generalitat de Catalunya through the CERCA Program. The

415 authors gratefully acknowledge the staff at the Kraaifontein Community Health Centre, the Ivan

416 Toms Centre for health and the Bloekombos Clinic, in the Cape Metro, South Africa, who worked

417 to collect and manage the data, our research team, collaborators, and especially all communities

- 418 and participants involved.
- 419

420 Funding

This work was supported by Mondial Diagnostics (Amsterdam, The Netherlands), the Severo Ochoa predoctoral fellowship by the Barcelona Institute of Global Health (ISGlobal) to A.S.L. and the European Respiratory Society (ERS) and the European Union (EU)'s H2020 research and innovation programme under the Marie Sklodowska-Curie grant agreement [847462] to E.L.V (This publication reflects only the author's view. The ERS, Research Executive Agency and EU are not responsible for any use that may be made of the information it contains).

427

428 Data Availability Statement

The data that support the findings of this study are available from the corresponding author uponreasonable request.

431

432 Supporting Information

- 433 Supporting Information file 1: Supplementary Table 1
- 434 Supporting Information file 2: Supplementary Table 2
- 435 Supporting Information file 3: Supplementary Table 3
- 436 Supporting Information file 4: Supplementary Figure 1
- 437 Supporting Information file 5: Supplementary Figure 2
- 438 Supporting Information file 6: Supplementary Figure 3
- 439 Supporting Information file 7: Supplementary Figures Legends

- 441 List of abbreviations
- 442 AIGHD: Amsterdam Institute for Global Health and Development
- 443 ART: antiretroviral therapy

- 444 AUC: area under the curve
- 445 CI: confidence interval
- 446 DALY: disability-adjusted live years
- 447 DBS: dried blood spots
- 448 EAC: enhanced adherence counselling
- 449 HIA: HIV infections averted
- 450 ICER: incremental cost-effectiveness ratios
- 451 IQR: interquartile range
- 452 IP-10: interferon gamma-induced protein 10
- 453 ISGlobal: Barcelona Institute for Global Health
- 454 LFA: lateral flow assay
- 455 LMIC: low- and middle-income countries
- 456 OR: odds ratio
- 457 PCR: Polymerase Chain Reaction
- 458 PLHIV: people living with human immunodeficiency virus
- 459 POC: point-of-care
- 460 PPV: positive predictive value
- 461 NPV: negative predictive value
- 462 SSA: Sub-Saharan Africa
- 463 VF: virological failure
- 464 VL: viral load
- 465
- 466

467 **References**

- 1. Updated Recommendations on Service Delivery for the Treatment and Care of People
- Living with HIV. Updat Recomm Serv Deliv Treat Care People Living with HIV
- 470 [Internet]. 2021 [cited 2021 Oct 8]; Available from:
- 471 https://www.ncbi.nlm.nih.gov/books/NBK570385/
- 2. Rupérez M, Pou C, Maculuve S, Cedeño S, Luis L, Rodríguez J, et al. Determinants of
- 473 virological failure and antiretroviral drug resistance in Mozambique. J Antimicrob

474		Chemother [Internet]. 2015 Sep 1 [cited 2022 Oct 23];70(9):2639-47. Available from:
475		https://pubmed.ncbi.nlm.nih.gov/26084302/
476	3.	Gupta RK, Gregson J, Parkin N, Haile-Selassie H, Tanuri A, Andrade Forero L, et al.
477		HIV-1 drug resistance before initiation or re-initiation of first-line antiretroviral therapy in
478		low-income and middle-income countries: a systematic review and meta-regression
479		analysis. Lancet Infect Dis [Internet]. 2018 Mar 1 [cited 2022 Oct 23];18(3):346-55.
480		Available from: https://pubmed.ncbi.nlm.nih.gov/29198909/
481	4.	Hamers RL, Rinke de Wit TF, Holmes CB. HIV drug resistance in low-income and
482		middle-income countries. Lancet HIV [Internet]. 2018 Oct 1 [cited 2022 Oct
483		23];5(10):e588–96. Available from:
484		http://www.thelancet.com/article/S2352301818301735/fulltext
485	5.	Global HIV & AIDS statistics — Fact sheet UNAIDS [Internet]. [cited 2022 Nov 2].
486		Available from: https://www.unaids.org/en/resources/fact-sheet
487	6.	Pham MD, Nguyen H V., Anderson D, Crowe S, Luchters S. Viral load monitoring for
488		people living with HIV in the era of test and treat: progress made and challenges ahead – a
489		systematic review. BMC Public Health [Internet]. 2022 Dec 1 [cited 2022 Oct
490		23];22(1):1–23. Available from:
491		https://bmcpublichealth.biomedcentral.com/articles/10.1186/s12889-022-13504-2
492	7.	Lecher S, Williams J, Fonjungo PN, Kim AA, Ellenberger D, Zhang G, et al. Progress
493		with Scale-Up of HIV Viral Load Monitoring — Seven Sub-Saharan African Countries,
494		January 2015–June 2016. MMWR Morb Mortal Wkly Rep. 2019 Dec 2;65(47):1332–5.
495	8.	Lecher SL, Fonjungo P, Ellenberger D, Toure CA, Alemnji G, Bowen N, et al. HIV Viral
496		Load Monitoring Among Patients Receiving Antiretroviral Therapy — Eight Sub-Saharan
497		Africa Countries, 2013–2018. MMWR Morb Mortal Wkly Rep [Internet]. 2021 May 28
498		[cited 2022 Dec 5];70(21):775–8. Available from:
499		https://www.cdc.gov/mmwr/volumes/70/wr/mm7021a2.htm
500	9.	Pastor L, Casellas A, Carrillo J, Alonso S, Parker E, Fuente-Soro L, et al. IP-10 Levels as

501		an Accurate Screening Tool to Detect Acute HIV Infection in Resource-Limited Settings.
502		Sci Rep [Internet]. 2017 Dec 1 [cited 2022 Feb 12];7(1). Available from:
503		https://pubmed.ncbi.nlm.nih.gov/28808319/
504	10.	Pastor L, Casellas A, Rupérez M, Carrillo J, Maculuve S, Jairoce C, et al. Interferon γ
505		Inducible Protein 10 (IP-10) as a Screening Tool to Optimize Human Immunodeficiency
506		Virus RNA Monitoring in Resource-Limited Settings. Clin Infect Dis [Internet]. 2017 Nov
507		15 [cited 2022 Feb 12];65(10):1670–5. Available from:
508		https://pubmed.ncbi.nlm.nih.gov/29020145/
509	11.	Kroeze S, Wit FW, Rossouw TM, Steel HC, Kityo CM, Siwale M, et al. Plasma
510		Biomarkers of Human Immunodeficiency Virus-Related Systemic Inflammation and
511		Immune Activation in Sub-Saharan Africa Before and During Suppressive Antiretroviral
512		Therapy. J Infect Dis [Internet]. 2019 Sep 9 [cited 2022 Oct 23];220(6):1029. Available
513		from: /pmc/articles/PMC6688057/
514	12.	Kehoe K, Boulle A, Tsondai PR, Euvrard J, Davies MA, Cornell M. Long-term virologic
515		responses to antiretroviral therapy among HIV-positive patients entering adherence clubs
516		in Khayelitsha, Cape Town, South Africa: a longitudinal analysis. J Int AIDS Soc.
517		2020;23(5).
518	13.	Euvrard J, Schulz T, Hilderbrand K, Bosland M, Osler M, Boulle A, et al. How accurately
519		do routinely reported HIV viral load suppression proportions reflect progress towards the
520		90-90-90 target in the population on antiretroviral treatment in Khayelitsha, South Africa?
521		South African Med J. 2019;109(3):174–7.
522	14.	Western Cape Department of Health. Routine antiretroviral programme report. 2021. Cape
523		Town; 2021.
524	15.	The Western Cape Consolidated Guidelines for HIV Treatment: Prevention of Mother- to-
525		Child Transmission of HIV (PMTCT), Children, Adolescents and Adults. 2020. 2020.
526	16.	Risk Assessment: COVID-19 Covid-19 Response [Internet]. Available from:
527		https://coronavirus.westerncape.gov.za/risk-assessment-covid-19

528	17.	Firth D. Bias reduction of maximum likelihood estimate. Biometrika; 1993. 80:27–38.
529	18.	Ministério de Saúde de Moçambique. Serviço Nacional de Saúde. Relatório Anual das
530		Actividades Relacionadas a HIV-SIDA 2021. Maputo, Moçambique; 2022.
531	19.	WHO methods and data sources for global burden of disease estimates 2000-2019
532		[Internet]. Geneva; 2020. Available from:
533		http://www.who.int/healthinfo/statistics/GlobalDALYmethods_2000_2011.pdf?ua=1
534	20.	Korenromp EL, Gobet B, Fazito E, Lara J, Bollinger L, Stover J. Impact and Cost of the
535		HIV/AIDS National Strategic Plan for Mozambique, 2015-2019—Projections with the
536		Spectrum/Goals Model. PLoS One [Internet]. 2015 Nov 1 [cited 2022 Oct
537		23];10(11):e0142908. Available from:
538		https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0142908
539	21.	Lipscomb J, Weinstein M, Torrance G. Time preference. In: Gold M, Siegel J, Russell L,
540		Weinstein M, editors. Cost-Effectiveness in Health and Medicine. Oxford, New York;
541		1996.
542	22.	Basu A, Ganiats T. Discounting in Cost-Effectiveness Analysis. In: Neumann P, Sanders
543		G, Russel L, JE S, Ganiats T, editors. Cost-Effectiveness in Health and Medicine. Second
544		Edi. New York: Oxford University Press; 2017. p. 277–88.
545	23.	Liu M, Guo S, Hibbert JM, Jain V, Singh N, Wilson NO, et al. CXCL10/IP-10 in
546		infectious diseases pathogenesis and potential therapeutic implications. Vol. 22, Cytokine
547		and Growth Factor Reviews. 2011. p. 121–30.
548	24.	Haroun RAH, Osman WH, Eessa AM. Interferon-y-induced protein 10 (IP-10) and serum
549		amyloid A (SAA) are excellent biomarkers for the prediction of COVID-19 progression
550		and severity. Life Sci [Internet]. 2021 Mar 15 [cited 2022 Oct 23];269. Available from:
551		https://pubmed.ncbi.nlm.nih.gov/33454365/
552	25.	Yek C, Gianella S, Plana M, Castro P, Scheffler K, García F, et al. Standard vaccines
553		increase HIV-1 transcription during antiretroviral therapy HHS Public Access. AIDS.
554		2016;30(15):2289–98.

26. Bentwich Z. Concurrent infections that rise the HIV viral load. J HIV Ther. 2003;8(3):72-555 75. 556 27. 557 Screening programmes: a short guide. Increase effectiveness, maximize benefits and 558 minimize harm. Copenhagen; 2020. Iino H, Hashiguchi M, Hori S. Estimating the range of incremental cost-effectiveness 559 28. thresholds for healthcare based on willingness to pay and GDP per capita: A systematic 560 561 review. PLoS One [Internet]. 2022 Apr 1 [cited 2022 Nov 8];17(4):e0266934. Available from: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0266934 562 563 29. GDP per capita (current US\$) - Mozambique | Data [Internet]. [cited 2022 Nov 8]. 564 Available from: https://data.worldbank.org/indicator/NY.GDP.PCAP.CD?locations=MZ Woods B, Revill P, Sculpher M, Claxton K. Country-Level Cost-Effectiveness 565 30. Thresholds: Initial Estimates and the Need for Further Research. Value Heal. 2016 Dec 566 1;19(8):929-35. 567 568 31. Ochalek J, Lomas J, Claxton K. Estimating health opportunity costs in low-income and middle-income countries: a novel approach and evidence from cross-country data. BMJ 569 570 Glob Heal [Internet]. 2018 [cited 2022 Nov 29];3:964. Available from: http://dx.doi.org/10.1136/bmjgh-2018-000964 571 32. Maxim LD, Niebo R, Utell MJ. Screening tests: a review with examples. Inhal Toxicol 572 [Internet]. 2014 Nov 1 [cited 2022 Nov 10];26(13):811. Available from: 573 /pmc/articles/PMC4389712/ 574 WHO guide for standardization of economic evaluations pf immunization programmes 575 33. [Internet]. Geneva; 2019. Available from: 576 577 https://www.who.int/immunization/documents/who_ivb_19.10/en/ 578 34. Médecins Sans Frontières (MSF). Achieving undetectable: what questions remain in scaling-up HIV. MSF Issue Br. 6, 1–20 (2015). 579 580 35. Médecins Sans Frontières (MSF). How low can we go? Pricing for HIV viral load testing

in low- and middle-income countries. 41, 8 (2013).

Roberts T. Cohn J. Bonner K. Hargreaves S. Scale-up of Routine Viral Load Testing in 582 36. Resource-Poor Settings: Current and Future Implementation Challenges. Clin Infect Dis 583 584 [Internet]. 2016 Apr 4 [cited 2022 Nov 7];62(8):1043. Available from: /pmc/articles/PMC4803106/ 585 37. Girdwood SJ, Crompton T, Sharma M, Dorward J, Garrett N, Drain PK, et al. Cost-586 effectiveness of adoption strategies for point of care HIV viral load monitoring in South 587 Africa. EClinicalMedicine [Internet]. 2020 [cited 2022 Nov 7];28:100607. Available 588 589 from: http://creativecommons.org/licenses/by/4.0/ 590 38. Nichols JH. Utilizing Point-of-Care Testing to Optimize Patient Care. EJIFCC [Internet]. 2021 [cited 2022 Oct 23];32(2):140. Available from: /pmc/articles/PMC8343046/ 591 592 39. Boeke CE, Joseph J, Atem C, Banda C, Coulibaly KD, Doi N, et al. Evaluation of near point-of-care viral load implementation in public health facilities across seven countries in 593 sub-Saharan Africa. 2021 [cited 2022 Nov 7]; Available from: 594 http://onlinelibrary.wiley.com/doi/10.1002/jia2.25663/full 595 596 40. WHO list of prequalified in vitro diagnostic products. Geneva: World Health Organization; 2020. 597 Id KS, Sharma M, Id JD, Naidoo J, Dlamini N, Moodley P, et al. Comparative cost 598 41. analysis of point-of-care versus laboratory-based testing to initiate and monitor HIV 599 treatment in South Africa. 2019 [cited 2022 Nov 7]; Available from: 600 601 https://doi.org/10.1371/journal.pone.0223669 602 42. Dorward J, Drain PK, Garrett N. Point-of-care viral load testing and differentiated HIV 603 care. Lancet HIV [Internet]. 2018 Jan 1 [cited 2022 Dec 5];5(1):e8–9. Available from: http://www.thelancet.com/article/S2352301817302114/fulltext 604 Moyo S, Mohammed T, Wirth KE, Prague M, Bennett K, Holme MP, et al. Point-of-Care 605 43. 606 Cepheid Xpert HIV-1 Viral Load Test in Rural African Communities Is Feasible and Reliable. J Clin Microbiol [Internet]. 2016 Dec 1 [cited 2022 Oct 23];54(12):3050. 607

- 608 Available from: /pmc/articles/PMC5121399/
- 609 44. Grimsrud A, Barnabas R V., Ehrenkranz P, Ford N. Evidence for scale up: The
- 610 differentiated care research agenda. Vol. 20, Journal of the International AIDS Society.
- 611 2017.